A point-of-care neutrophil elastase activity assay identifies bronchiectasis severity, airway infection and risk of exacerbation.
Aged
Biomarkers
/ metabolism
Bronchiectasis
/ diagnosis
Cohort Studies
Disease Progression
Female
Forced Expiratory Volume
Humans
Leukocyte Elastase
/ metabolism
Linear Models
Lung
/ physiopathology
Male
Middle Aged
Neutrophils
/ metabolism
Point-of-Care Testing
Severity of Illness Index
Spain
Sputum
/ metabolism
United Kingdom
Journal
The European respiratory journal
ISSN: 1399-3003
Titre abrégé: Eur Respir J
Pays: England
ID NLM: 8803460
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
12
02
2019
accepted:
14
03
2019
pubmed:
4
6
2019
medline:
30
10
2020
entrez:
2
6
2019
Statut:
epublish
Résumé
Neutrophil elastase activity in sputum can identify patients at high risk of airway infection and exacerbations in bronchiectasis. Application of this biomarker in clinical practice is limited, because no point-of-care test is available. We tested whether a novel semi-quantitative lateral flow device (neutrophil elastase airway test stick - NEATstik®) can stratify bronchiectasis patients according to severity, airway infection and exacerbation risk. Sputum samples from 124 patients with stable bronchiectasis enrolled in the UK and Spain were tested using the NEATstik®, which scores neutrophil elastase concentration from 0 (<8 µg·mL Patients had a median age of 69 years and forced expiratory volume in 1 s (FEV A novel lateral flow device provides assessment of neutrophil elastase activity from sputum in minutes and identifies patients at increasing risk of airway infection and future exacerbations.
Identifiants
pubmed: 31151955
pii: 13993003.00303-2019
doi: 10.1183/13993003.00303-2019
pii:
doi:
Substances chimiques
Biomarkers
0
Leukocyte Elastase
EC 3.4.21.37
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Chief Scientist Office
ID : SCAF/17/03
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright ©ERS 2019.
Déclaration de conflit d'intérêts
Conflict of interest: A. Shoemark has nothing to disclose. Conflict of interest: E. Cant has nothing to disclose. Conflict of interest: L. Carreto has nothing to disclose. Conflict of interest: A. Smith has nothing to disclose. Conflict of interest: M. Oriano has nothing to disclose. Conflict of interest: H.R. Keir has nothing to disclose. Conflict of interest: L. Perea has nothing to disclose. Conflict of interest: E. Canto has nothing to disclose. Conflict of interest: L. Terranova has nothing to disclose. Conflict of interest: S. Vidal has nothing to disclose. Conflict of interest: K. Moffitt was employed by Proaxsis, during the conduct of the study. Conflict of interest: S. Aliberti has nothing to disclose. Conflict of interest: O Sibila has nothing to disclose. Conflict of interest: J.D. Chalmers reports grants and personal fees from GlaxoSmithKline, Boehringer Ingelheim, Pfizer, Bayer Healthcare, Grifols and Insmed, grants from AstraZeneca, personal fees from Napp and Aradigm Corporation, outside the submitted work.